Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma

[1]  P. Canoll,et al.  Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL , 2017, Nature Communications.

[2]  M. Halatsch,et al.  Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma , 2017, Expert opinion on drug discovery.

[3]  P. Canoll,et al.  Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. , 2017, Cancer research.

[4]  Georg Karpel-Massler,et al.  BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma , 2017, Oncotarget.

[5]  D. Altieri,et al.  Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma , 2017, Oncotarget.

[6]  B. Teh,et al.  Dual modulation of MCL-1 and mTOR determines the response to sunitinib , 2017, The Journal of clinical investigation.

[7]  P. Canoll,et al.  Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo , 2016, Oncotarget.

[8]  L. Greene,et al.  A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers , 2016, Clinical Cancer Research.

[9]  P. Canoll,et al.  Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo , 2016, Oncotarget.

[10]  P. Canoll,et al.  TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo , 2015, Oncotarget.

[11]  Timothy C Ryken,et al.  Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.

[12]  P. Canoll,et al.  Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo , 2015, Oncotarget.

[13]  S. Ramaswamy,et al.  Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer , 2015, Proceedings of the National Academy of Sciences.

[14]  J. C. Ghosh,et al.  Adaptive mitochondrial reprogramming and resistance to PI3K therapy. , 2015, Journal of the National Cancer Institute.

[15]  P. Canoll,et al.  PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma , 2014, PloS one.

[16]  P. Canoll,et al.  PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD , 2014, Molecular Cancer Research.

[17]  R. Bronson,et al.  Inhibition of EGFR Induces a c‐MET‐Driven Stem Cell Population in Glioblastoma , 2014, Stem cells.

[18]  S. Fulda,et al.  Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein* , 2013, The Journal of Biological Chemistry.

[19]  M. Siegelin.  Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer? , 2013, Cancer letters.

[20]  J. Laterra,et al.  In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells. , 2013, Translational oncology.

[21]  I. Pollack,et al.  YM-155 Potentiates the Effect of ABT-737 in Malignant Human Glioma Cells via Survivin and Mcl-1 Downregulation in an EGFR-Dependent Context , 2013, Molecular Cancer Therapeutics.

[22]  J. Maris,et al.  ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. , 2012, Cancer cell.

[23]  H. Seol,et al.  MET signaling regulates glioblastoma stem cells. , 2012, Cancer research.

[24]  M. Siegelin.  Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis , 2012, Expert opinion on therapeutic targets.

[25]  I. Pollack,et al.  ABT-737 Synergizes with Bortezomib to Induce Apoptosis, Mediated by Bid Cleavage, Bax Activation, and Mitochondrial Dysfunction in an Akt-Dependent Context in Malignant Human Glioma Cell Lines , 2012, Journal of Pharmacology and Experimental Therapeutics.

[26]  Daniel P. Stewart,et al.  Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration , 2012, Nature Cell Biology.

[27]  M. Konopleva,et al.  MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex , 2012, Leukemia.

[28]  S. Combs,et al.  p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737 , 2011, Apoptosis.

[29]  A. Eastman,et al.  Multiple BH3 Mimetics Antagonize Antiapoptotic MCL1 Protein by Inducing the Endoplasmic Reticulum Stress Response and Up-regulating BH3-only Protein NOXA* , 2011, The Journal of Biological Chemistry.

[30]  Martin Glas,et al.  c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype , 2011, Proceedings of the National Academy of Sciences.

[31]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[32]  T. Kuwana,et al.  BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak* , 2010, The Journal of Biological Chemistry.

[33]  V. Seifert,et al.  The Pan-Bcl-2 Inhibitor (−)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma , 2010, Molecular Cancer Research.

[34]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[35]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[36]  Philippe Pierre,et al.  SUnSET, a nonradioactive method to monitor protein synthesis , 2009, Nature Methods.

[37]  Qiuyan Wang,et al.  ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells , 2009, Proceedings of the National Academy of Sciences.

[38]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[39]  O. Wiestler,et al.  Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins , 2008, Oncogene.

[40]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[41]  E. Campo,et al.  The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. , 2007, Blood.

[42]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.